Ionis Pharmaceuticals, Inc. (IONS)
USD 25.51
(-7.47%)
USD 25.51
(-7.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -353.73 Million USD | 13.93% |
| 2022 | -411 Million USD | -1270.0% |
| 2021 | -30 Million USD | 82.56% |
| 2020 | -172 Million USD | -146.99% |
| 2019 | 366 Million USD | 696.36% |
| 2018 | -61.37 Million USD | -350.15% |
| 2017 | 24.53 Million USD | 152.97% |
| 2016 | -46.31 Million USD | 38.87% |
| 2015 | -75.76 Million USD | -58.73% |
| 2014 | -47.73 Million USD | 7.62% |
| 2013 | -51.66 Million USD | 25.04% |
| 2012 | -68.92 Million USD | 3.06% |
| 2011 | -71.1 Million USD | -47.03% |
| 2010 | -48.35 Million USD | -75.6% |
| 2009 | -27.53 Million USD | -110.86% |
| 2008 | -13.06 Million USD | 66.47% |
| 2007 | -38.94 Million USD | 42.82% |
| 2006 | -68.11 Million USD | -19.12% |
| 2005 | -57.18 Million USD | 51.48% |
| 2004 | -117.85 Million USD | -49.22% |
| 2003 | -78.97 Million USD | -55.43% |
| 2002 | -50.81 Million USD | -10.22% |
| 2001 | -46.1 Million USD | -59.03% |
| 2000 | -28.99 Million USD | 32.74% |
| 1999 | -43.1 Million USD | -32.62% |
| 1998 | -32.5 Million USD | -3.17% |
| 1997 | -31.5 Million USD | -7.51% |
| 1996 | -29.3 Million USD | -14.45% |
| 1995 | -25.6 Million USD | -13.78% |
| 1994 | -22.5 Million USD | -22.95% |
| 1993 | -18.3 Million USD | 15.28% |
| 1992 | -21.6 Million USD | -105.71% |
| 1991 | -10.5 Million USD | -133.33% |
| 1990 | -4.5 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -66.09 Million USD | 55.8% |
| 2024 Q1 | -149.51 Million USD | -2341.83% |
| 2023 Q2 | -91 Million USD | 20.18% |
| 2023 Q4 | -6.12 Million USD | 95.72% |
| 2023 Q3 | -143 Million USD | -57.14% |
| 2023 Q1 | -114 Million USD | 45.19% |
| 2023 FY | -353.73 Million USD | 13.93% |
| 2022 Q4 | -208 Million USD | -251.72% |
| 2022 Q3 | -59.13 Million USD | 30.84% |
| 2022 Q1 | -57.47 Million USD | -126.01% |
| 2022 Q2 | -85.51 Million USD | -48.78% |
| 2022 FY | -411 Million USD | -1270.0% |
| 2021 Q3 | -85.84 Million USD | -17.65% |
| 2021 Q4 | 221 Million USD | 357.43% |
| 2021 Q1 | -91.97 Million USD | -299.87% |
| 2021 Q2 | -72.96 Million USD | 20.66% |
| 2021 FY | -30 Million USD | 82.56% |
| 2020 Q1 | -61.12 Million USD | -123.42% |
| 2020 Q2 | -51.75 Million USD | 15.33% |
| 2020 Q3 | -36.53 Million USD | 29.4% |
| 2020 FY | -172 Million USD | -146.99% |
| 2020 Q4 | -23 Million USD | 37.05% |
| 2019 Q3 | 2.52 Million USD | 113.28% |
| 2019 Q4 | 261 Million USD | 10244.83% |
| 2019 Q1 | 121.53 Million USD | 1027.2% |
| 2019 FY | 366 Million USD | 696.36% |
| 2019 Q2 | -19 Million USD | -115.63% |
| 2018 Q1 | -3.3 Million USD | -94.98% |
| 2018 Q3 | -18.57 Million USD | 63.06% |
| 2018 Q4 | 10.78 Million USD | 158.06% |
| 2018 Q2 | -50.28 Million USD | -1423.21% |
| 2018 FY | -61.37 Million USD | -350.15% |
| 2017 Q4 | -1.69 Million USD | -112.17% |
| 2017 Q2 | -1.67 Million USD | -111.95% |
| 2017 Q1 | 13.98 Million USD | -66.01% |
| 2017 FY | 24.53 Million USD | 152.97% |
| 2017 Q3 | 13.9 Million USD | 932.38% |
| 2016 Q3 | 16.1 Million USD | 132.92% |
| 2016 Q4 | 41.15 Million USD | 155.49% |
| 2016 FY | -46.31 Million USD | 38.87% |
| 2016 Q1 | -54.65 Million USD | 13.17% |
| 2016 Q2 | -48.92 Million USD | 10.48% |
| 2015 Q3 | -48.13 Million USD | -207.82% |
| 2015 FY | -75.76 Million USD | -58.73% |
| 2015 Q1 | -9.33 Million USD | -192.56% |
| 2015 Q4 | -62.94 Million USD | -30.75% |
| 2015 Q2 | 44.64 Million USD | 578.52% |
| 2014 FY | -47.73 Million USD | 7.62% |
| 2014 Q3 | -21.49 Million USD | -223.2% |
| 2014 Q4 | 10.08 Million USD | 146.9% |
| 2014 Q2 | -6.65 Million USD | 77.58% |
| 2014 Q1 | -29.66 Million USD | -49.4% |
| 2013 Q2 | -7.92 Million USD | -587.88% |
| 2013 Q1 | 1.62 Million USD | 106.22% |
| 2013 FY | -51.66 Million USD | 25.04% |
| 2013 Q4 | -19.85 Million USD | 22.14% |
| 2013 Q3 | -25.5 Million USD | -221.71% |
| 2012 Q2 | 3.69 Million USD | 120.03% |
| 2012 Q1 | -18.45 Million USD | 0.86% |
| 2012 Q3 | -28.04 Million USD | -858.82% |
| 2012 Q4 | -26.11 Million USD | 6.87% |
| 2012 FY | -68.92 Million USD | 3.06% |
| 2011 Q2 | -14.06 Million USD | 12.71% |
| 2011 Q3 | -22.31 Million USD | -58.72% |
| 2011 FY | -71.1 Million USD | -47.03% |
| 2011 Q4 | -18.61 Million USD | 16.58% |
| 2011 Q1 | -16.1 Million USD | -1.58% |
| 2010 Q1 | -4.88 Million USD | 58.19% |
| 2010 FY | -48.35 Million USD | -75.6% |
| 2010 Q2 | -18.67 Million USD | -282.62% |
| 2010 Q3 | -8.94 Million USD | 52.08% |
| 2010 Q4 | -15.85 Million USD | -77.24% |
| 2009 Q3 | -10.39 Million USD | -115.37% |
| 2009 FY | -27.53 Million USD | -110.86% |
| 2009 Q4 | -11.67 Million USD | -12.26% |
| 2009 Q2 | -4.82 Million USD | -651.87% |
| 2009 Q1 | -642 Thousand USD | -119.89% |
| 2008 Q2 | -3.13 Million USD | 64.52% |
| 2008 Q1 | -8.83 Million USD | -4.6% |
| 2008 FY | -13.06 Million USD | 66.47% |
| 2008 Q3 | -4.32 Million USD | -38.01% |
| 2008 Q4 | 3.22 Million USD | 174.65% |
| 2007 Q2 | -19.66 Million USD | 5.94% |
| 2007 Q4 | -8.44 Million USD | -183.95% |
| 2007 Q3 | 10.05 Million USD | 151.15% |
| 2007 Q1 | -20.9 Million USD | -24.89% |
| 2007 FY | -38.94 Million USD | 42.82% |
| 2006 FY | -68.11 Million USD | -19.12% |
| 2006 Q4 | -16.73 Million USD | 8.37% |
| 2006 Q3 | -18.26 Million USD | -6.79% |
| 2006 Q2 | -17.1 Million USD | -6.78% |
| 2006 Q1 | -16.01 Million USD | -86.06% |
| 2005 Q1 | -23.5 Million USD | 54.62% |
| 2005 Q3 | -12.14 Million USD | 6.03% |
| 2005 Q2 | -12.92 Million USD | 45.02% |
| 2005 FY | -57.18 Million USD | 51.48% |
| 2005 Q4 | -8.6 Million USD | 29.12% |
| 2004 Q3 | -22.38 Million USD | -4.87% |
| 2004 Q1 | -22.33 Million USD | -3.98% |
| 2004 FY | -117.85 Million USD | -49.22% |
| 2004 Q2 | -21.34 Million USD | 4.45% |
| 2004 Q4 | -51.79 Million USD | -131.45% |
| 2003 Q3 | -19.06 Million USD | 2.32% |
| 2003 Q4 | -21.48 Million USD | -12.66% |
| 2003 Q2 | -19.52 Million USD | -3.21% |
| 2003 Q1 | -18.91 Million USD | -68.17% |
| 2003 FY | -78.97 Million USD | -55.43% |
| 2002 FY | -50.81 Million USD | -10.22% |
| 2002 Q1 | -9.71 Million USD | -26.26% |
| 2002 Q3 | -17.5 Million USD | -41.9% |
| 2002 Q4 | -11.24 Million USD | 35.77% |
| 2002 Q2 | -12.33 Million USD | -26.97% |
| 2001 Q3 | -4.7 Million USD | 71.41% |
| 2001 FY | -46.1 Million USD | -59.03% |
| 2001 Q4 | -7.69 Million USD | -63.52% |
| 2001 Q2 | -16.46 Million USD | 4.47% |
| 2001 Q1 | -17.23 Million USD | -72.13% |
| 2000 Q3 | 206 Thousand USD | 102.52% |
| 2000 Q1 | -11 Million USD | 11.93% |
| 2000 Q2 | -8.17 Million USD | 25.74% |
| 2000 FY | -28.99 Million USD | 32.74% |
| 2000 Q4 | -10.01 Million USD | -4960.19% |
| 1999 Q4 | -12.5 Million USD | -54.32% |
| 1999 Q3 | -8.1 Million USD | 32.5% |
| 1999 Q2 | -12 Million USD | -14.29% |
| 1999 FY | -43.1 Million USD | -32.62% |
| 1999 Q1 | -10.5 Million USD | -7.14% |
| 1998 Q2 | -13 Million USD | -18.18% |
| 1998 FY | -32.5 Million USD | -3.17% |
| 1998 Q4 | -9.8 Million USD | -1080.0% |
| 1998 Q3 | 1 Million USD | 107.69% |
| 1998 Q1 | -11 Million USD | -4.76% |
| 1997 Q3 | -2.6 Million USD | 73.2% |
| 1997 FY | -31.5 Million USD | -7.51% |
| 1997 Q1 | -8.9 Million USD | 8.25% |
| 1997 Q2 | -9.7 Million USD | -8.99% |
| 1997 Q4 | -10.5 Million USD | -303.85% |
| 1996 FY | -29.3 Million USD | -14.45% |
| 1996 Q4 | -9.7 Million USD | -44.78% |
| 1996 Q3 | -6.7 Million USD | 17.28% |
| 1996 Q2 | -8.1 Million USD | -68.75% |
| 1996 Q1 | -4.8 Million USD | 22.58% |
| 1995 Q1 | -6.1 Million USD | 45.54% |
| 1995 Q4 | -6.2 Million USD | 16.22% |
| 1995 Q2 | -6 Million USD | 1.64% |
| 1995 Q3 | -7.4 Million USD | -23.33% |
| 1995 FY | -25.6 Million USD | -13.78% |
| 1994 FY | -22.5 Million USD | -22.95% |
| 1994 Q4 | -11.2 Million USD | -124.0% |
| 1994 Q2 | -4.8 Million USD | -6.67% |
| 1994 Q1 | -4.5 Million USD | -2.27% |
| 1994 Q3 | -5 Million USD | -4.17% |
| 1993 Q4 | -4.4 Million USD | 0.0% |
| 1993 FY | -18.3 Million USD | 15.28% |
| 1993 Q1 | -5.1 Million USD | 31.08% |
| 1993 Q2 | -4.6 Million USD | 9.8% |
| 1993 Q3 | -4.4 Million USD | 4.35% |
| 1992 Q4 | -7.4 Million USD | -51.02% |
| 1992 FY | -21.6 Million USD | -105.71% |
| 1992 Q2 | -4.2 Million USD | 16.0% |
| 1992 Q1 | -5 Million USD | 0.0% |
| 1992 Q3 | -4.9 Million USD | -16.67% |
| 1991 FY | -10.5 Million USD | -133.33% |
| 1991 Q3 | -2.4 Million USD | -4.35% |
| 1991 Q1 | -1.3 Million USD | 78.33% |
| 1991 Q2 | -2.3 Million USD | -76.92% |
| 1991 Q4 | -5 Million USD | -108.33% |
| 1990 Q2 | 500 Thousand USD | 0.0% |
| 1990 FY | -4.5 Million USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 Q3 | 500 Thousand USD | 0.0% |
| 1990 Q4 | -6 Million USD | -1300.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -46.25 Million USD | -664.722% |
| Jaguar Health, Inc. | -34.29 Million USD | -931.553% |
| Keros Therapeutics, Inc. | -169.94 Million USD | -108.149% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -523.214% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -25.358% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 3062.067% |
| ContextLogic Inc. | -328 Million USD | -7.845% |
| MiMedx Group, Inc. | 37.11 Million USD | 1053.039% |
| MEI Pharma, Inc. | 14.54 Million USD | 2532.471% |
| AlloVir, Inc. | -181.33 Million USD | -95.074% |
| Novavax, Inc. | -566.51 Million USD | 37.56% |
| Aptorum Group Limited | -10.52 Million USD | -3261.388% |
| Ardelyx, Inc. | -63.27 Million USD | -459.027% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | -72.55% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -12754.378% |
| Vaxcyte, Inc. | -468.04 Million USD | 24.423% |
| Precigen, Inc. | -88.92 Million USD | -297.794% |
| Pharming Group N.V. | -4.87 Million USD | -7149.243% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | -111.419% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | -1088.769% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -1626.27% |
| Avidity Biosciences, Inc. | -235.59 Million USD | -50.141% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -1721.612% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -1355.283% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -1355.283% |
| Bicycle Therapeutics plc | -189.94 Million USD | -86.227% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -29.096% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | -1107.064% |
| Acelyrin, Inc. | -422.06 Million USD | 16.19% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | -834.089% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | -854.376% |
| Senti Biosciences, Inc. | -92.72 Million USD | -281.475% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | -208.2% |
| AbCellera Biologics Inc. | -237.2 Million USD | -49.123% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | -932.276% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | -105.918% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -11086.907% |
| Chimerix, Inc. | -93.06 Million USD | -280.089% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | -971.227% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -1916.82% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -684.719% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -597.789% |
| Elevation Oncology, Inc. | -45.44 Million USD | -678.369% |
| Alkermes plc | 414.12 Million USD | 185.417% |
| Fortress Biotech, Inc. | -142.34 Million USD | -148.507% |
| Fortress Biotech, Inc. | -142.34 Million USD | -148.507% |
| Agenus Inc. | -159.54 Million USD | -121.706% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | -262.08% |
| Dyadic International, Inc. | -8.22 Million USD | -4198.192% |
| ImmuCell Corporation | -5.74 Million USD | -6053.883% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -29575.336% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | -163.135% |
| Lantern Pharma Inc. | -17.87 Million USD | -1878.625% |
| Immix Biopharma, Inc. | -16.14 Million USD | -2091.485% |
| Incyte Corporation | 620.52 Million USD | 157.005% |
| IO Biotech, Inc. | -91.44 Million USD | -286.831% |
| Janux Therapeutics, Inc. | -72.97 Million USD | -384.701% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -1660.745% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | -565.827% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | -174.235% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -4061.04% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | -321.539% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 7.035% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 29.859% |
| NextCure, Inc. | -67.63 Million USD | -422.983% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -3248.765% |
| Onconetix, Inc. | -36.03 Million USD | -881.64% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | -747.989% |
| Opthea Limited | -191.84 Million USD | -84.385% |
| PDS Biotechnology Corporation | -43.04 Million USD | -721.763% |
| PureTech Health plc | -146.19 Million USD | -141.951% |
| Pyxis Oncology, Inc. | -82.19 Million USD | -330.349% |
| Seer, Inc. | -103.46 Million USD | -241.89% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -2743069.026% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -1323.805% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -8873.255% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -1109.003% |
| Wave Life Sciences Ltd. | -67.99 Million USD | -420.222% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -703.749% |
| C4 Therapeutics, Inc. | -139.03 Million USD | -154.425% |
| ChromaDex Corporation | -5.59 Million USD | -6217.735% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -5028.008% |
| Caribou Biosciences, Inc. | -116.05 Million USD | -204.785% |
| CRISPR Therapeutics AG | -222.53 Million USD | -58.953% |
| Precision BioSciences, Inc. | -43.73 Million USD | -708.785% |
| Fate Therapeutics, Inc. | -190.51 Million USD | -85.674% |
| Innoviva, Inc. | 176.7 Million USD | 300.177% |
| Summit Therapeutics Inc. | -89.73 Million USD | -294.19% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | -437.919% |
| Aadi Bioscience, Inc. | -71.93 Million USD | -391.749% |
| ESSA Pharma Inc. | -32.13 Million USD | -1000.793% |
| GlycoMimetics, Inc. | -39.27 Million USD | -800.643% |
| GT Biopharma, Inc. | -13.57 Million USD | -2505.554% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | -61.358% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 507.467% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | -586.774% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -3459.495% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | -36.229% |
| Aptose Biosciences Inc. | -52.35 Million USD | -575.625% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -2352.92% |
| Soligenix, Inc. | -7.69 Million USD | -4495.125% |
| Century Therapeutics, Inc. | -146.54 Million USD | -141.378% |
| Kura Oncology, Inc. | -165.8 Million USD | -113.342% |
| TScan Therapeutics, Inc. | -93.45 Million USD | -278.491% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -4152.074% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -14153.886% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -5355.429% |
| Autolus Therapeutics plc | -195.02 Million USD | -81.374% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -317.839% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | -380.207% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -1573.669% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | -55.804% |
| GRI Bio, Inc. | -11.38 Million USD | -3006.437% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -7733.311% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | -169.626% |
| IGM Biosciences, Inc. | -263.46 Million USD | -34.263% |
| INmune Bio, Inc. | -29.74 Million USD | -1089.368% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -219.785% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -829.027% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -2113.668% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -2142.939% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | -478.955% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | -228.984% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -28.16% |
| Coherus BioSciences, Inc. | -203.19 Million USD | -74.081% |
| Verastem, Inc. | -92.08 Million USD | -284.138% |
| Abeona Therapeutics Inc. | -47.13 Million USD | -650.461% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | -92.093% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | -198.809% |
| Histogen Inc. | -10.64 Million USD | -3223.593% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -2186.265% |
| Surrozen, Inc. | -45.78 Million USD | -672.674% |
| Organovo Holdings, Inc. | -15.08 Million USD | -2244.757% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -6849.187% |
| Ovid Therapeutics Inc. | -59.28 Million USD | -496.696% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -589.613% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -1299.248% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -4534.315% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | -106.518% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | -630.124% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | -352.311% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -2223.995% |
| Apollomics, Inc. | -54.83 Million USD | -545.092% |
| Amarin Corporation plc | -67.58 Million USD | -423.362% |
| Mesoblast Limited | -58.79 Million USD | -501.643% |
| Turnstone Biologics Corp. | -59.03 Million USD | -499.217% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | -113.695% |
| Synaptogenix, Inc. | -8.31 Million USD | -4154.705% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -2325.134% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | -285.785% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -7282.5% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -3905.442% |
| Exelixis, Inc. | 170.88 Million USD | 306.999% |
| Better Therapeutics, Inc. | -38.26 Million USD | -824.494% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | -128.12% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 31.596% |
| NLS Pharmaceutics AG | -11.8 Million USD | -2895.919% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -4298.584% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -1079.375% |
| Gritstone bio, Inc. | -154.63 Million USD | -128.753% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -413.687% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -1965.812% |
| Avid Bioservices, Inc. | -18.67 Million USD | -1793.832% |
| Insmed Incorporated | -709.62 Million USD | 50.153% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -2154.524% |
| MediWound Ltd. | -15.29 Million USD | -2213.473% |
| OmniAb, Inc. | -69.41 Million USD | -409.558% |
| Alector, Inc. | -151.74 Million USD | -133.116% |
| Seres Therapeutics, Inc. | -107.98 Million USD | -227.579% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -578.319% |
| Zai Lab Limited | -366.57 Million USD | 3.504% |
| Revance Therapeutics, Inc. | -316.77 Million USD | -11.665% |
| Aura Biosciences, Inc. | -84.99 Million USD | -316.197% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | -44.086% |
| Immunic, Inc. | -99.22 Million USD | -256.5% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | -147.091% |
| Veracyte, Inc. | -85.79 Million USD | -312.297% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | -25.519% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -2389.303% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -5035.492% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -1782.282% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 161.138% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -1289.738% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 1011.628% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1814.39% |
| Galecto, Inc. | -39.9 Million USD | -786.43% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -740.733% |
| Fortrea Holdings Inc. | 63.1 Million USD | 660.586% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | -151.864% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | -1124.912% |
| XBiotech Inc. | -37.51 Million USD | -843.029% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | -413.687% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | -427.011% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | -227.813% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -1277.883% |
| Theravance Biopharma, Inc. | -53.29 Million USD | -563.758% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 37.856% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | -350.657% |
| Vaxxinity, Inc. | -58.28 Million USD | -506.897% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | -241.079% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -1489.574% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | -309.334% |
| NexImmune, Inc. | -29.19 Million USD | -1111.716% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -6193.98% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -2325.902% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 108.74% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -1289.41% |
| Scopus BioPharma Inc. | -11.71 Million USD | -2919.494% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | -178.392% |
| Ainos, Inc. | -13.2 Million USD | -2578.475% |
| Pluri Inc. | -22.15 Million USD | -1496.399% |
| Prothena Corporation plc | -191.03 Million USD | -85.164% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | -156.256% |
| Celularity Inc. | -192.28 Million USD | -83.959% |
| Rallybio Corporation | -78.93 Million USD | -348.145% |
| Cue Biopharma, Inc. | -52.14 Million USD | -578.306% |
| MeiraGTx Holdings plc | -137.06 Million USD | -158.082% |
| Omeros Corporation | -164.53 Million USD | -114.994% |
| Humacyte, Inc. | -100.04 Million USD | -253.564% |
| Immunocore Holdings plc | -59.64 Million USD | -493.019% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -1805.976% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -1344.798% |
| Blueprint Medicines Corporation | -486.27 Million USD | 27.258% |
| CalciMedica, Inc. | -21.87 Million USD | -1517.051% |
| Cabaletta Bio, Inc. | -74.66 Million USD | -373.788% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | -169.027% |
| Scholar Rock Holding Corporation | -171.29 Million USD | -106.503% |
| Sana Biotechnology, Inc. | -326.9 Million USD | -8.207% |
| Pulmatrix, Inc. | -14.74 Million USD | -2299.796% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | -889.593% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | -298.049% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 31.353% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | -423.649% |
| Cytokinetics, Incorporated | -496.2 Million USD | 28.713% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -927.717% |
| Nutriband Inc. | -4.87 Million USD | -7160.578% |
| Protara Therapeutics, Inc. | -43.61 Million USD | -711.066% |
| Vor Biopharma Inc. | -126.03 Million USD | -180.658% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 108.339% |
| Evogene Ltd. | -26.39 Million USD | -1240.343% |
| ProKidney Corp. | -151.52 Million USD | -133.451% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -448.121% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -4498.529% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 41.76% |
| CorMedix Inc. | -48.95 Million USD | -622.52% |
| BioLineRx Ltd. | -49.69 Million USD | -611.816% |
| Tango Therapeutics, Inc. | -114.17 Million USD | -209.819% |
| Galectin Therapeutics Inc. | -38.07 Million USD | -829.108% |
| Atai Life Sciences N.V. | -125.47 Million USD | -181.922% |
| Renovaro Biosciences Inc. | -81.63 Million USD | -333.284% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | -334.51% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | -42.067% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -1050.716% |
| MediciNova, Inc. | -9.9 Million USD | -3472.935% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | -179.909% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -4784.115% |
| GeoVax Labs, Inc. | -26.74 Million USD | -1222.704% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -52.585% |
| Biomea Fusion, Inc. | -126.13 Million USD | -180.438% |
| PTC Therapeutics, Inc. | -349.4 Million USD | -1.239% |
| Mereo BioPharma Group plc | -28.41 Million USD | -1144.827% |
| Cullinan Oncology, Inc. | -191.08 Million USD | -85.113% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | -53.826% |
| Absci Corporation | -115.51 Million USD | -206.22% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -1182.234% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | -213.404% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | -46.072% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -1303.913% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | -70.067% |
| Allakos Inc. | -196.05 Million USD | -80.423% |
| Imunon, Inc. | -21.03 Million USD | -1581.991% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | -219.643% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 429.72% |
| BioAtla, Inc. | -129.68 Million USD | -172.757% |
| NLS Pharmaceutics AG | -11.8 Million USD | -2895.919% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -2132.721% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | -7.931% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | -747.095% |
| XOMA Corporation | -41.84 Million USD | -745.273% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | -236.127% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -191.148% |
| aTyr Pharma, Inc. | -54.91 Million USD | -544.094% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | -304.6% |
| Akero Therapeutics, Inc. | -172.87 Million USD | -104.622% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | -39.017% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -1547.862% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -4207.081% |
| Akari Therapeutics, Plc | -16.8 Million USD | -2004.784% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -3999999.513% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 204.786% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -5313.664% |
| UroGen Pharma Ltd. | -65.53 Million USD | -439.749% |
| Sutro Biopharma, Inc. | -89.27 Million USD | -296.212% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -4770.293% |
| Orgenesis Inc. | -53.63 Million USD | -559.501% |
| Entera Bio Ltd. | -8.89 Million USD | -3878.518% |
| GH Research PLC | -41.22 Million USD | -758.11% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -1275.953% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | -325.909% |
| Xencor, Inc. | -138.63 Million USD | -155.145% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -6762.437% |
| Replimune Group, Inc. | -234.77 Million USD | -50.669% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -1545.936% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -2435.335% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -5313.664% |
| Portage Biotech Inc. | -18.25 Million USD | -1837.928% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -4784.115% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | -237.011% |
| OncoCyte Corporation | -25.13 Million USD | -1307.264% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -3029.009% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -2987.441% |
| Purple Biotech Ltd. | 22.27 Million USD | 1688.299% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -4608.866% |
| scPharmaceuticals Inc. | -55.39 Million USD | -538.548% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -1771.816% |
| HilleVax, Inc. | -133.34 Million USD | -165.274% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -2835.762% |
| Tharimmune, Inc. | -9.45 Million USD | -3641.108% |
| Genprex, Inc. | -31.07 Million USD | -1038.29% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | -87.96% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | -1027.354% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -46139.216% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -6394.13% |
| OKYO Pharma Limited | -15.74 Thousand USD | -2245843.264% |
| Savara Inc. | -60 Million USD | -489.481% |
| Curis, Inc. | -48.33 Million USD | -631.875% |
| Daré Bioscience, Inc. | -30.83 Million USD | -1046.989% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -6679.97% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -4760.932% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | -1198.092% |
| BeiGene, Ltd. | -1.2 Billion USD | 70.711% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -1674.034% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 27.393% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | -277.707% |
| Erasca, Inc. | -141.52 Million USD | -149.942% |
| bluebird bio, Inc. | -244.26 Million USD | -44.816% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -7713.829% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 281.922% |
| DBV Technologies S.A. | -76.43 Million USD | -362.804% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -7713.829% |
| Moderna, Inc. | -4.23 Billion USD | 91.655% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -730.177% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -5461.792% |
| Molecular Templates, Inc. | -10.46 Million USD | -3279.801% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | -426.094% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 6.109% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | -146.827% |
| Spruce Biosciences, Inc. | -51.99 Million USD | -580.342% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | -128.889% |
| Cogent Biosciences, Inc. | -208.13 Million USD | -69.956% |
| MacroGenics, Inc. | -168.24 Million USD | -110.248% |
| RenovoRx, Inc. | -11.39 Million USD | -3003.984% |
| Adicet Bio, Inc. | -152.03 Million USD | -132.659% |
| Prime Medicine, Inc. | -191.29 Million USD | -84.916% |
| Aditxt, Inc. | -26.06 Million USD | -1257.241% |
| Adagene Inc. | -23.71 Million USD | -1391.282% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -4738.923% |
| Quantum-Si incorporated | -111.17 Million USD | -218.185% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | -1017.701% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -2326.503% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 389.909% |
| SciSparc Ltd. | -5.77 Million USD | -6027.317% |
| Vericel Corporation | -6.46 Million USD | -5372.308% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -3986.216% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -1430.002% |
| Generation Bio Co. | -138.56 Million USD | -155.285% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -326.027% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | -309.126% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | -46.714% |
| Invivyd, Inc. | -207.78 Million USD | -70.24% |
| Relay Therapeutics, Inc. | -373 Million USD | 5.166% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -3671.71% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 1746.711% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -3338.612% |
| 2seventy bio, Inc. | -216.7 Million USD | -63.233% |
| ADMA Biologics, Inc. | 21.63 Million USD | 1735.216% |
| Clene Inc. | -40.54 Million USD | -772.546% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -1369.109% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | -545.54% |
| GeoVax Labs, Inc. | -26.74 Million USD | -1222.704% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | -1.048% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | -863.002% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 2300.224% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | -241.102% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -940.321% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | -107.737% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 48.308% |
| Evaxion Biotech A/S | -22.19 Million USD | -1493.594% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | -329.378% |
| Verve Therapeutics, Inc. | -223.12 Million USD | -58.535% |
| Trevena, Inc. | -35.28 Million USD | -902.409% |
| Surrozen, Inc. | -45.78 Million USD | -672.674% |
| Tyra Biosciences, Inc. | -79.94 Million USD | -342.467% |
| Cingulate Inc. | -22.75 Million USD | -1454.229% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 4821.436% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -691.927% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -4195.999% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | -244.907% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | -382.059% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | -469.852% |
| Clearmind Medicine Inc. | -8.74 Million USD | -3946.629% |
| Kronos Bio, Inc. | -121.83 Million USD | -190.347% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | -364.237% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -11960.409% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -250.829% |
| Statera Biopharma, Inc. | -98.34 Million USD | -259.687% |
| ImmunityBio, Inc. | -362.25 Million USD | 2.352% |
| Korro Bio, Inc. | -84.53 Million USD | -318.447% |
| Kineta, Inc. | -15.72 Million USD | -2149.761% |
| BioVie Inc. | -32.17 Million USD | -999.237% |
| Codexis, Inc. | -68.06 Million USD | -419.664% |
| Celularity Inc. | -192.28 Million USD | -83.959% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | -58.903% |
| Celcuity Inc. | -66.23 Million USD | -434.091% |
| Virax Biolabs Group Limited | -6.49 Million USD | -5344.955% |
| Cibus, Inc. | -318.88 Million USD | -10.928% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | -722.628% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -945.178% |
| IN8bio, Inc. | -30.33 Million USD | -1066.002% |
| Kodiak Sciences Inc. | -277.32 Million USD | -27.553% |
| Annexon, Inc. | -143.72 Million USD | -146.119% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | -185.748% |
| Assembly Biosciences, Inc. | -64.64 Million USD | -447.18% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -1408.83% |
| Eyenovia, Inc. | -25.4 Million USD | -1292.284% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 1183.732% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -6259.763% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | -347.007% |
| Arcellx, Inc. | -89.88 Million USD | -293.558% |
| Cardiff Oncology, Inc. | -45.41 Million USD | -678.935% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | -157.808% |
| Regulus Therapeutics Inc. | -31.1 Million USD | -1037.066% |
| Moolec Science SA | -6.65 Million USD | -5216.206% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | -478.576% |
| Geron Corporation | -193.94 Million USD | -82.388% |
| LAVA Therapeutics N.V. | -43.25 Million USD | -717.816% |
| Royalty Pharma plc | 1.49 Billion USD | 123.706% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | -115.476% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -3692.186% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -1515.599% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | -106.912% |
| Humacyte, Inc. | -100.04 Million USD | -253.564% |
| Structure Therapeutics Inc. | -102.77 Million USD | -244.179% |
| 89bio, Inc. | -151.2 Million USD | -133.942% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | -341.434% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -2332.806% |
| Genelux Corporation | -24.16 Million USD | -1363.811% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | -942.744% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | -105.956% |
| Notable Labs, Ltd. | -14.65 Million USD | -2313.386% |
| Liquidia Corporation | -73.38 Million USD | -382.026% |
| Mustang Bio, Inc. | -50.72 Million USD | -597.335% |
| Immunovant, Inc. | -282.7 Million USD | -25.122% |
| Quantum-Si incorporated | -111.17 Million USD | -218.185% |
| Arbutus Biopharma Corporation | -78.1 Million USD | -352.902% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -1563.281% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -246.753% |
| Acasti Pharma Inc. | -11.31 Million USD | -3027.033% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -1443.25% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -2113.668% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | -65.253% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -9540.857% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -2126.678% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | -1113.191% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | -754.751% |
| PepGen Inc. | -84.76 Million USD | -317.302% |
| Moleculin Biotech, Inc. | -29.63 Million USD | -1093.784% |
| United Therapeutics Corporation | 1.18 Billion USD | 129.853% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -1444.875% |
| Solid Biosciences Inc. | -104.31 Million USD | -239.098% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | -978.178% |
| Immuneering Corporation | -58.41 Million USD | -505.568% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -6849.187% |
| Silo Pharma, Inc. | -3.85 Million USD | -9074.467% |
| Belite Bio, Inc | -31.66 Million USD | -1016.995% |
| XOMA Corporation | -41.84 Million USD | -745.273% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | -423.889% |
| Bionomics Limited | -17.89 Billion USD | 98.023% |
| Apogee Therapeutics, Inc. | -93 Million USD | -280.343% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 1091.396% |
| uniQure N.V. | -282.87 Million USD | -25.05% |
| Cassava Sciences, Inc. | -105.95 Million USD | -233.843% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -4738.923% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -173.142% |
| Forte Biosciences, Inc. | -32.48 Million USD | -988.869% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -4157.317% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | -1103.368% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -6259.763% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -2389.303% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -3879.413% |
| Altimmune, Inc. | -95.92 Million USD | -268.741% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -381.305% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 1091.396% |
| Compugen Ltd. | -12.99 Million USD | -2622.675% |
| Peak Bio, Inc. | -1356.23 USD | -26081759.272% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | -613.108% |
| Benitec Biopharma Inc. | -22.49 Million USD | -1472.832% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | -45.987% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | -1089.168% |
| Zura Bio Limited | -62.63 Million USD | -464.721% |
| PolyPid Ltd. | -22.86 Million USD | -1446.902% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -2073.323% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | -1089.168% |
| Instil Bio, Inc. | -159.16 Million USD | -122.235% |
| argenx SE | -425.04 Million USD | 16.779% |
| Immunome, Inc. | -109.53 Million USD | -222.953% |
| Compass Therapeutics, Inc. | -50.36 Million USD | -602.361% |
| Verona Pharma plc | -67.83 Million USD | -421.488% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -1257.368% |
| Shattuck Labs, Inc. | -91.95 Million USD | -284.669% |
| CervoMed Inc. | -7.81 Million USD | -4427.515% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | -383.833% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -2555.431% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -634.276% |
| Moolec Science SA | -6.65 Million USD | -5216.206% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -2050.538% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | -161.583% |
| AnaptysBio, Inc. | -164.41 Million USD | -115.15% |
| Design Therapeutics, Inc. | -78.19 Million USD | -352.398% |
| Leap Therapeutics, Inc. | -87.04 Million USD | -306.395% |
| NeurAxis, Inc. | -6.66 Million USD | -5207.679% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | -773.429% |
| Lumos Pharma, Inc. | -36.61 Million USD | -866.106% |
| Achilles Therapeutics plc | -75.25 Million USD | -370.042% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -1257.368% |
| 180 Life Sciences Corp. | -13.47 Million USD | -2524.597% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 6960.137% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -11960.409% |
| Nutriband Inc. | -4.87 Million USD | -7160.578% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | -219.309% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | -537.938% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | -595.826% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | -435.152% |
| MoonLake Immunotherapeutics | -54.12 Million USD | -553.566% |
| Palisade Bio, Inc. | -13.07 Million USD | -2606.427% |
| Tourmaline Bio, Inc. | -45.4 Million USD | -678.987% |
| Beam Therapeutics Inc. | -176.48 Million USD | -100.431% |
| Neurogene Inc. | -55.58 Million USD | -536.4% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | -224.065% |
| AEON Biopharma, Inc. | -48.42 Million USD | -630.409% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | -265.764% |
| Sesen Bio, Inc. | -25.9 Million USD | -1265.278% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | -323.482% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -2710.304% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 23.196% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | -388.314% |
| Athira Pharma, Inc. | -125.46 Million USD | -181.933% |
| Vaccinex, Inc. | -22.88 Million USD | -1445.685% |
| HCW Biologics Inc. | -25.71 Million USD | -1275.463% |
| XOMA Corporation | -41.84 Million USD | -745.273% |
| Nektar Therapeutics | -137.42 Million USD | -157.399% |
| Arvinas, Inc. | -401.5 Million USD | 11.898% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -3999999.513% |
| Merus N.V. | -156.54 Million USD | -125.958% |
| Omega Therapeutics, Inc. | -100.26 Million USD | -252.809% |
| Quince Therapeutics, Inc. | -34.62 Million USD | -921.75% |
| Rezolute, Inc. | -70.42 Million USD | -402.293% |
| Clene Inc. | -40.54 Million USD | -772.546% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -2059.725% |
| BeyondSpring Inc. | -23.11 Million USD | -1430.371% |
| Synlogic, Inc. | -55.16 Million USD | -541.268% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -1872.949% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -3168.016% |
| Peak Bio, Inc. | -1356.23 USD | -26081759.272% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | -773.343% |
| Krystal Biotech, Inc. | -109.72 Million USD | -222.373% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | -173.066% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | -3.124% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -7353.298% |
| MannKind Corporation | 8.67 Million USD | 4176.17% |
| Ikena Oncology, Inc. | -75.41 Million USD | -369.032% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -3566.736% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | -426.149% |
| Gossamer Bio, Inc. | -183.75 Million USD | -92.497% |
| CohBar, Inc. | -12.38 Million USD | -2755.356% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | -597.362% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | -1182.234% |
| Legend Biotech Corporation | -439.48 Million USD | 19.513% |
| Mural Oncology plc | -194.63 Million USD | -81.737% |
| Biora Therapeutics, Inc. | -67.14 Million USD | -426.831% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -2090.92% |
| Disc Medicine, Inc. | -91.12 Million USD | -288.181% |
| Champions Oncology, Inc. | -7.35 Million USD | -4708.728% |
| REGENXBIO Inc. | -268.12 Million USD | -31.926% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -3200.278% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -534.425% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | -807.916% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | -209.321% |
| Vaxart, Inc. | -83.34 Million USD | -324.406% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -4051.757% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | -726.586% |
| Cellectis S.A. | -106.62 Million USD | -231.748% |
| Longeveron Inc. | -21.02 Million USD | -1582.106% |
| Repare Therapeutics Inc. | -116.22 Million USD | -204.352% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -32.076% |
| Inozyme Pharma, Inc. | -75.64 Million USD | -367.618% |
| Revolution Medicines, Inc. | -487.18 Million USD | 27.393% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -5217.649% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | -704.773% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -374.232% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | -407.977% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -3112.515% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 108.212% |
| Denali Therapeutics Inc. | -196.69 Million USD | -79.833% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -3986.216% |
| Veru Inc. | -93.78 Million USD | -277.182% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -1416.267% |
| Cingulate Inc. | -22.75 Million USD | -1454.229% |
| Passage Bio, Inc. | -108.38 Million USD | -226.352% |
| Context Therapeutics Inc. | -25.07 Million USD | -1310.822% |
| Exicure, Inc. | -14.99 Million USD | -2258.829% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | -71.66% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | -771.299% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -3540.345% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | -91.872% |
| Nuvalent, Inc. | -149.49 Million USD | -136.621% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -4205.113% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | -298.654% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -1602.753% |
| OmniAb, Inc. | -69.41 Million USD | -409.558% |
| Anew Medical, Inc. | -1.3 Million USD | -27092.43% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -2669.791% |
| Lipocine Inc. | -17.93 Million USD | -1872.734% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | -416.296% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | -364.505% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | -829.027% |
| G1 Therapeutics, Inc. | -39.52 Million USD | -794.907% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -1480.281% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 38.996% |
| Ocugen, Inc. | -65.53 Million USD | -439.79% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | -276.846% |
| Q32 Bio Inc. | -92.1 Million USD | -284.063% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -1549.937% |
| Alumis Inc. Common Stock | -158.17 Million USD | -123.633% |
| Equillium, Inc. | -14.52 Million USD | -2335.822% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | -466.82% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -4375.698% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -1775.049% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -653.402% |
| Evelo Biosciences, Inc. | -108.46 Million USD | -226.121% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -2855.134% |
| Dominari Holdings Inc. | -21.79 Million USD | -1522.912% |
| Edesa Biotech, Inc. | -9.22 Million USD | -3735.404% |
| vTv Therapeutics Inc. | -25.5 Million USD | -1287.068% |
| Bio-Techne Corporation | 206.68 Million USD | 271.144% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 9.645% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 284.206% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | -167.416% |
| Candel Therapeutics, Inc. | -38.39 Million USD | -821.388% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | -134.102% |
| Nkarta, Inc. | -131.65 Million USD | -168.69% |
| BioCardia, Inc. | -11.64 Million USD | -2937.874% |
| Iterum Therapeutics plc | -47.46 Million USD | -645.197% |